a Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis Who Participated in the Study CACZ885G2301E1
This trial is active, not recruiting.
|Condition||systemic juvenile idiopathic arthritis|
|Start date||November 2014|
|End date||December 2016|
|Trial size||11 participants|
|Trial identifier||NCT02334748, CACZ885GFR01|
The objective of this extension protocol is to collect safety data and to provide continuous Ilaris® (canakinumab) to patients in France who completed study CACZ885G2301E1 for a maximum of 24 months or until a decision regarding reimbursement in France is effective for Ilaris® in the SJIA indication.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
time frame: every 4 weeks up to 1 year
Male or female participants of any age.
Inclusion Criteria: - Patients who have completed the international CACZ885G2301E1 Exclusion Criteria: - History of recurring infections - Hypersensitivity to the active substance or to any of the excipients other protocol-defined inclusion/exclusion criteria may apply
|Official title||A French Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Who Participated in the International Phase III Study CACZ885G2301E1|
Call for more information